
Molecular Imaging-Based Monitoring of Tumor-Selective Virus ReplicationAward last edited on: 10/30/14
Sponsored Program
SBIRAwarding Agency
NIH : NINDSTotal Award Amount
$224,741Award Phase
1Solicitation Topic Code
-----Principal Investigator
Douglas J JollyCompany Information
Tocagen Inc
3030 Bunker Hill Street Suite 230
San Diego, CA 92109
San Diego, CA 92109
(858) 412-8400 |
info@tocagen.com |
www.tocagen.com |
Location: Single
Congr. District: 50
County: San Diego
Congr. District: 50
County: San Diego
Phase I
Contract Number: 1R43NS086335-01A1Start Date: 5/1/14 Completed: 4/30/15
Phase I year
2014Phase I Amount
$224,741Thesaurus Terms:
Adverse Effects;Award;Base;Biological Assay;Bioluminescence Imaging;Brain Neoplasms;Cancer Cell;Cancer Patient;Cell Killing;Cells;Cessation Of Life;Chemotherapeutic Agent;Chemotherapy;Chronic;Clinic;Clinical;Clinical Research;Clinical Trial Protocol Document;Clinical Trials;Consultations;Cytolysis;Cytosine Deaminase;Cytotoxic Agent;Data;Development;Dose;Drug Formulations;Environment;Enzymes;Event;Excision;Flucytosine;Fluorouracil;Future;Ganciclovir;Gene Therapy;Gene Transfer;Genes;Glioma;Goals;Health System;Herpes Simplex Infections;Human;Image;Imaging Modality;Imaging Techniques;Immune;Immune Response;In Vitro;In Vivo;Infection;Inflammation;Injection Of Therapeutic Agent;Insight;Killings;Los Angeles;Magnetic Resonance Imaging;Malignant Neoplasm Of Brain;Malignant Neoplasms;Measurable;Measurement;Mediating;Metastatic Malignant Neoplasm To Brain;Methods;Minimally Invasive;Modality;Modeling;Molecular Imaging;Monitor;Multi-Institutional Clinical Trial;Necrosis;Neoplastic Cell;Neuro-Oncology;Neurosurgery;Non-Invasive Monitor;Normal Cell;Novel;Novel Strategies;Ohio;Oncolytic;Oral Administration;Patients;Phase;Population;Positron-Emission Tomography;Pre-Clinical;Preclinical Study;Premature;Principal Investigator;Prodrugs;Proteins;Public Health Relevance;Recurrence;Regimen;Relating To Nervous System;Resistance;Retroviral Vector;Safety;San Francisco;Schedule;Simplexvirus;Small Business Innovation Research Grant;Subcutaneous;Suicide Gene;Surgically-Created Resection Cavity;Symptomatic Improvement;Techniques;Technology;Testing;Therapeutic;Therapeutic Index;Thymidine Kinase;Time;Transduction Efficiency;Transgenes;Translating;Treatment Strategy;Tumor;Tumor Growth;Tumor Subtype;Valacyclovir;Validation;Vector;Vector Biodistribution;Vertebral Column;Viral;Virus;Virus Replication;Wit;Work;Xenograft Model;Yeasts;
Phase II
Contract Number: ----------Start Date: 00/00/00 Completed: 00/00/00